Mitigating and Managing Immune Mediated AEs in Patients Receiving Checkpoint Inhibitor Treatment

1.00 CME
1.00 AAPA
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Mitigating and Managing Immune Mediated AEs in Patients Receiving Checkpoint Inhibitor Treatment  Online Enduring Material Activity


Mitigating and Managing Immune Mediated AEs in Patients Receiving Checkpoint Inhibitor Treatment
Online Enduring Material Activity
Release date: 11/19/2021
Expiration date: 11/19/2022

Activity Overview

Early recognition and characterization of treatment-related adverse events (TRAE) has long been a cornerstone of determining the value of oncology treatment for patients and healthcare professionals. Important clinical benefits of checkpoint inhibitors are associated with a unique spectrum of immune-mediated adverse events (imAEs). ImAEs include dermatologic, gastrointestinal, hepatic, endocrine and less common inflammatory events, and are believed to arise from general immunologic enhancement. Rare fulminant and even fatal toxicities may occur with immune checkpoint inhibitors. Therefore, prompt recognition and management of imAEs is important.

Target Audience

This activity is designed to meet the needs of Oncology professionals, physicians, physician assistants, nurses, and nurse navigators.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Explain the unique profile of imAEs associated with checkpoint inhibitors and the timing of onset of the imAEs.
  • Anticipate and identify imAEs and promptly initiate guideline and evidence-based management strategies to optimize patient outcomes.
  • Identify, mitigate, and manage imAEs in patients receiving checkpoint inhibitor treatment, through adaptive learning-based case examples.

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at


Aung Naing, MD, FACP
Department of Investigational Cancer Therapeutics
The University of Texas
MD Anderson Cancer Center
Houston TX

Dr. Naing has experience in developing first-in-human, early phase clinical trials including several immunotherapy-based trials. His research focuses on clinical translation of basic immunobiology and is aimed at identifying biomarkers to predict response, resistance, and immune-related adverse events associated with immunotherapies. Dr. Naing has authored and co-authored more than 250 original research articles.

AKHCredit provided by AKH, Inc., Advancing Knowledge in Healthcare

ACCME Jointly accredited In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Center of Excellence Media, LLC. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit being awarded: 1.0 ANCC contact hours

aapaAAPA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Commercial Support

This activity is supported by an educational grant from Merck Sharp & Dohme Corp.


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.





Aung Naing MD, FACP

Professor,Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center












CytomX Therapeutics, Novartis, Genome & Company, OncoSec

KEYNOTE-695, Kymab, and STCube Pharmaceuticals; SPOUSE: Takeda,

CSL, Behring, Horizon, and Pharming

NCI, EMD Serono, MedImmune, Healios Onc. Nutrition, Atterocor/Millendo,

Amplimmune, ARMO BioSciences, Karyopharm Therapeutics, Incyte,

Novartis, Regeneron, Merck, Bristol-Myers Squibb, Pfizer, CytomX

Therapeutics, Neon Therapeutics, Calithera Biosciences, TopAlliance

Biosciences, Eli Lilly, Kymab, PsiOxus, Arcus Biosciences,

NeoImmuneTech, ImmuneOncia, and Surface Oncology; SPOUSE:

Immune Deficiency Foundation, Jeffery Modell Foundation and chao

physician-scientist, and Baxalta

Dorothy Caputo, MA, BSN, RN

Vice President of Continuing Education and Compliance


Nothing to disclose

COE Planners and Reviewers


Nothing to disclose

AKH Planners and Reviewers


Nothing to disclose

All of the relevant financial relationships listed for these individuals have been mitigated.



Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.